TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,558,939 | +520.4% | 733,662 | +966.0% | 0.00% | – |
| Q2 2023 | $1,057,152 | -95.1% | 68,825 | -92.8% | 0.00% | -100.0% |
| Q1 2023 | $21,594,875 | +6.5% | 960,199 | -0.4% | 0.01% | 0.0% |
| Q4 2022 | $20,279,103 | -28.4% | 964,294 | -16.2% | 0.01% | -16.7% |
| Q3 2022 | $28,341,000 | -11.3% | 1,150,190 | -12.8% | 0.01% | -25.0% |
| Q2 2022 | $31,958,000 | -14.6% | 1,318,936 | -9.2% | 0.01% | 0.0% |
| Q1 2022 | $37,417,000 | +34.1% | 1,451,978 | +61.5% | 0.01% | +60.0% |
| Q4 2021 | $27,901,000 | +32.3% | 898,876 | +3.3% | 0.01% | +25.0% |
| Q3 2021 | $21,094,000 | +1213.4% | 869,870 | +690.0% | 0.00% | – |
| Q2 2021 | $1,606,000 | -32.1% | 110,104 | +16.3% | 0.00% | – |
| Q1 2021 | $2,365,000 | -91.4% | 94,703 | -90.6% | 0.00% | -100.0% |
| Q4 2020 | $27,482,000 | – | 1,008,328 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |